contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vicore-pharma-to-present-at-upcoming-investor-conferences-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vicore Pharma är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för lung- och hjärt-kärlsjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. Vicore Pharma grundades 2000 och har sitt huvudkontor i Göteborg.

Vicore Pharma Holding

Stockholm, March 09, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced...

<div class="mfn-body">Stockholm, March 09, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:<ul><li>DNB Carnegie Healthcare Conference Location:&nbsp;Stockholm, Sweden Format:&nbsp;Presentation and 1×1 meetings Presentation Date and Time:&nbsp;Thursday, March 12 at 9:10 AM CET Participant: Mikael Nygård, COO</li></ul><ul><li>10th Annual Nordic-American Healthcare Conference Location: New York, USA Format:&nbsp;Presentation and 1×1 meetings Presentation Date and Time:&nbsp;Wednesday, March 25 at 2:00 PM EST Participant: Megan Richards, VP of IR and Comms</li></ul>For more information, please contact: Megan Richards, VP of IR and Comms, +1&nbsp;978&nbsp;269-4372, <a href="mailto:megan.richards@vicorepharma.com" rel="noopener">megan.richards@vicorepharma.com</a> Hans Jeppsson, CFO, +46 70 553 14 65,&nbsp;<a href="mailto:hans.jeppsson@vicorepharma.com" rel="noopener">hans.jeppsson@vicorepharma.com</a> About Vicore Pharma&nbsp; Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. &nbsp; Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. <a href="http://www.vicorepharma.com/" rel="noopener">www.vicorepharma.com</a></div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a class="mfn-generated mfn-primary" href="https://storage.mfn.se/11e45034-fb97-4f86-8bb7-23aeb2457398/vicore-pharma-to-present-at-upcoming-investor-conferences.pdf" rel="noopener">Vicore Pharma to Present at Upcoming Investor Conferences</a></div>

Vicore Pharma to Present at Upcoming Investor Conferences

Neste

Finnair

Kemira

Orthex

Nokian Tyres

Kesko

Tokmanni Group

Puuilo

Oljeprisets inverkan på Helsingforsbörsen: historik, påverkansmekanismer och risker

Nordea Bank

Aktieägare i Nordea? Nordeas bolagsstämma hålls virtuellt – nu är det lättare än någonsin att delta

Inflation överraskar i euroområdet redan före oljeprisets inverkan

Priset på svart guld steg på grund av problem i Hormuzsundet

Stagflation fruktas, men ekonomins strukturer motverkar det